Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
QuantumLeap Healthcare Collaborative
Novartis
Mayo Clinic
Kivu Bioscience Inc.
Canadian Cancer Trials Group
Institut Curie
City of Hope Medical Center
Boundless Bio, Inc.
Ocellaris Pharma, Inc.
M.D. Anderson Cancer Center
Transgene
Novartis
Hadassah Medical Organization
Valo Therapeutics Oy
Institut Bergonié
Numab Therapeutics AG
NextPoint Therapeutics, Inc.